Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAAC: Drug Sensitivity in Hematological Malignancies
NCT05001386Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Open-label trial in myeloproliferative disorder (MPD), lymphoproliferative disorder (LPD), acute myeloid leukemia (AML) and 4 more, sponsored by Hospices Civils de Lyon. Primary endpoints: Evaluation of the sensitivity of 10 anti-cancer drugs by Flow Cytometry at 3 years and Evaluation of the sensitivity of 10 anti-cancer drugs by monitoring blasts in mouse blood at 3 years. Status: unknown.
02
Conditions
myeloproliferative disorder (MPD)lymphoproliferative disorder (LPD)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05001386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001386.